Literature DB >> 30531922

The molecular landscape of glioma in patients with Neurofibromatosis 1.

Fulvio D'Angelo1,2, Michele Ceccarelli2,3, Luciano Garofano1,2, Jing Zhang1, Véronique Frattini1, Francesca P Caruso2,3, Genevieve Lewis1, Kristin D Alfaro4, Luc Bauchet5, Giulia Berzero6, David Cachia7,8, Mario Cangiano2, Laurent Capelle9, John de Groot10, Francesco DiMeco11,12,13, François Ducray14, Walid Farah15, Gaetano Finocchiaro16, Stéphane Goutagny17, Carlos Kamiya-Matsuoka10, Cinzia Lavarino18, Hugues Loiseau19, Véronique Lorgis20, Carlo E Marras21, Ian McCutcheon10, Do-Hyun Nam22,23, Susanna Ronchi6, Veronica Saletti24, Romuald Seizeur25, John Slopis10, Mariona Suñol26, Fanny Vandenbos27, Pascale Varlet28,29, Dominique Vidaud30, Colin Watts31, Viviane Tabar32, David E Reuss33,34, Seung-Ki Kim35, David Meyronet36, Karima Mokhtari6, Hector Salvador37, Krishna P Bhat10, Marica Eoli16, Marc Sanson6, Anna Lasorella38,39,40, Antonio Iavarone41,42,43.   

Abstract

Neurofibromatosis type 1 (NF1) is a common tumor predisposition syndrome in which glioma is one of the prevalent tumors. Gliomagenesis in NF1 results in a heterogeneous spectrum of low- to high-grade neoplasms occurring during the entire lifespan of patients. The pattern of genetic and epigenetic alterations of glioma that develops in NF1 patients and the similarities with sporadic glioma remain unknown. Here, we present the molecular landscape of low- and high-grade gliomas in patients affected by NF1 (NF1-glioma). We found that the predisposing germline mutation of the NF1 gene was frequently converted to homozygosity and the somatic mutational load of NF1-glioma was influenced by age and grade. High-grade tumors harbored genetic alterations of TP53 and CDKN2A, frequent mutations of ATRX associated with Alternative Lengthening of Telomere, and were enriched in genetic alterations of transcription/chromatin regulation and PI3 kinase pathways. Low-grade tumors exhibited fewer mutations that were over-represented in genes of the MAP kinase pathway. Approximately 50% of low-grade NF1-gliomas displayed an immune signature, T lymphocyte infiltrates, and increased neo-antigen load. DNA methylation assigned NF1-glioma to LGm6, a poorly defined Isocitrate Dehydrogenase 1 wild-type subgroup enriched with ATRX mutations. Thus, the profiling of NF1-glioma defined a distinct landscape that recapitulates a subset of sporadic tumors.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30531922      PMCID: PMC6857804          DOI: 10.1038/s41591-018-0263-8

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  79 in total

Review 1.  The NF1 somatic mutational landscape in sporadic human cancers.

Authors:  Charlotte Philpott; Hannah Tovell; Ian M Frayling; David N Cooper; Meena Upadhyaya
Journal:  Hum Genomics       Date:  2017-06-21       Impact factor: 4.639

2.  Incidence and mortality of neurofibromatosis: a total population study in Finland.

Authors:  Elina Uusitalo; Jussi Leppävirta; Anna Koffert; Sakari Suominen; Jussi Vahtera; Tero Vahlberg; Minna Pöyhönen; Juha Peltonen; Sirkku Peltonen
Journal:  J Invest Dermatol       Date:  2014-10-29       Impact factor: 8.551

3.  Distinctive Cancer Associations in Patients With Neurofibromatosis Type 1.

Authors:  Elina Uusitalo; Matti Rantanen; Roope A Kallionpää; Minna Pöyhönen; Jussi Leppävirta; Heli Ylä-Outinen; Vincent M Riccardi; Eero Pukkala; Janne Pitkäniemi; Sirkku Peltonen; Juha Peltonen
Journal:  J Clin Oncol       Date:  2016-02-29       Impact factor: 44.544

Review 4.  Neurofibromatosis type 1.

Authors:  David H Gutmann; Rosalie E Ferner; Robert H Listernick; Bruce R Korf; Pamela L Wolters; Kimberly J Johnson
Journal:  Nat Rev Dis Primers       Date:  2017-02-23       Impact factor: 52.329

5.  Birth incidence and prevalence of tumor-prone syndromes: estimates from a UK family genetic register service.

Authors:  D G Evans; E Howard; C Giblin; T Clancy; H Spencer; S M Huson; F Lalloo
Journal:  Am J Med Genet A       Date:  2010-02       Impact factor: 2.802

6.  Systematic MRI in NF1 children under six years of age for the diagnosis of optic pathway gliomas. Study and outcome of a French cohort.

Authors:  Gaelle Blanchard; Marie-Pierre Lafforgue; Laurence Lion-François; Isabelle Kemlin; Diana Rodriguez; Pierre Castelnau; Maryline Carneiro; Pierre Meyer; François Rivier; Sébastien Barbarot; Yves Chaix
Journal:  Eur J Paediatr Neurol       Date:  2015-12-17       Impact factor: 3.140

Review 7.  Mechanisms in the pathogenesis of malignant tumours in neurofibromatosis type 1.

Authors:  Hilde Brems; Eline Beert; Thomy de Ravel; Eric Legius
Journal:  Lancet Oncol       Date:  2009-05       Impact factor: 41.316

8.  Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma.

Authors:  Michele Ceccarelli; Floris P Barthel; Tathiane M Malta; Thais S Sabedot; Sofie R Salama; Bradley A Murray; Olena Morozova; Yulia Newton; Amie Radenbaugh; Stefano M Pagnotta; Samreen Anjum; Jiguang Wang; Ganiraju Manyam; Pietro Zoppoli; Shiyun Ling; Arjun A Rao; Mia Grifford; Andrew D Cherniack; Hailei Zhang; Laila Poisson; Carlos Gilberto Carlotti; Daniela Pretti da Cunha Tirapelli; Arvind Rao; Tom Mikkelsen; Ching C Lau; W K Alfred Yung; Raul Rabadan; Jason Huse; Daniel J Brat; Norman L Lehman; Jill S Barnholtz-Sloan; Siyuan Zheng; Kenneth Hess; Ganesh Rao; Matthew Meyerson; Rameen Beroukhim; Lee Cooper; Rehan Akbani; Margaret Wrensch; David Haussler; Kenneth D Aldape; Peter W Laird; David H Gutmann; Houtan Noushmehr; Antonio Iavarone; Roel G W Verhaak
Journal:  Cell       Date:  2016-01-28       Impact factor: 41.582

9.  Non-optic glioma in adults and children with neurofibromatosis 1.

Authors:  Laura Sellmer; Said Farschtschi; Marco Marangoni; Manraj K S Heran; Patricia Birch; Ralph Wenzel; Jan M Friedman; Victor-Felix Mautner
Journal:  Orphanet J Rare Dis       Date:  2017-02-15       Impact factor: 4.123

10.  Risk of benign tumours of nervous system, and of malignant neoplasms, in people with neurofibromatosis: population-based record-linkage study.

Authors:  O O Seminog; M J Goldacre
Journal:  Br J Cancer       Date:  2012-12-20       Impact factor: 7.640

View more
  59 in total

Review 1.  An update on the central nervous system manifestations of neurofibromatosis type 1.

Authors:  J Stephen Nix; Jaishri Blakeley; Fausto J Rodriguez
Journal:  Acta Neuropathol       Date:  2019-04-08       Impact factor: 17.088

Review 2.  Genetic and molecular epidemiology of adult diffuse glioma.

Authors:  Annette M Molinaro; Jennie W Taylor; John K Wiencke; Margaret R Wrensch
Journal:  Nat Rev Neurol       Date:  2019-06-21       Impact factor: 42.937

3.  Genetic basis of neurofibromatosis type 1 and related conditions, including mosaicism.

Authors:  Eric Legius; Hilde Brems
Journal:  Childs Nerv Syst       Date:  2020-06-29       Impact factor: 1.475

4.  Patients with High-Grade Gliomas and Café-au-Lait Macules: Is Neurofibromatosis Type 1 the Only Diagnosis?

Authors:  L Guerrini-Rousseau; M Suerink; J Grill; E Legius; K Wimmer; L Brugières
Journal:  AJNR Am J Neuroradiol       Date:  2019-05-09       Impact factor: 3.825

Review 5.  Molecularly Targeted Agents in the Therapy of Pediatric Brain Tumors.

Authors:  Miriam Bornhorst; Eugene I Hwang
Journal:  Paediatr Drugs       Date:  2020-02       Impact factor: 3.022

6.  CRL4AMBRA1 is a master regulator of D-type cyclins.

Authors:  Daniele Simoneschi; Gergely Rona; Nan Zhou; Yeon-Tae Jeong; Shaowen Jiang; Giacomo Milletti; Arnaldo A Arbini; Alfie O'Sullivan; Andrew A Wang; Sorasicha Nithikasem; Sarah Keegan; Yik Siu; Valentina Cianfanelli; Emiliano Maiani; Francesca Nazio; Francesco Cecconi; Francesco Boccalatte; David Fenyö; Drew R Jones; Luca Busino; Michele Pagano
Journal:  Nature       Date:  2021-04-14       Impact factor: 49.962

7.  Network-based identification of key master regulators associated with an immune-silent cancer phenotype.

Authors:  Raghvendra Mall; Mohamad Saad; Jessica Roelands; Darawan Rinchai; Khalid Kunji; Hossam Almeer; Wouter Hendrickx; Francesco M Marincola; Michele Ceccarelli; Davide Bedognetti
Journal:  Brief Bioinform       Date:  2021-11-05       Impact factor: 11.622

8.  Nonoptic pathway tumors in children with neurofibromatosis type 1.

Authors:  Jasia Mahdi; Manu S Goyal; Jennifer Griffith; Stephanie M Morris; David H Gutmann
Journal:  Neurology       Date:  2020-04-16       Impact factor: 9.910

9.  Pathway-based classification of glioblastoma uncovers a mitochondrial subtype with therapeutic vulnerabilities.

Authors:  Luciano Garofano; Simona Migliozzi; Young Taek Oh; Fulvio D'Angelo; Ryan D Najac; Aram Ko; Brulinda Frangaj; Francesca Pia Caruso; Kai Yu; Jinzhou Yuan; Wenting Zhao; Anna Luisa Di Stefano; Franck Bielle; Tao Jiang; Peter Sims; Mario L Suvà; Fuchou Tang; Xiao-Dong Su; Michele Ceccarelli; Marc Sanson; Anna Lasorella; Antonio Iavarone
Journal:  Nat Cancer       Date:  2021-01-11

Review 10.  Neurofibromatosis in the Era of Precision Medicine: Development of MEK Inhibitors and Recent Successes with Selumetinib.

Authors:  Robert Galvin; Adrienne L Watson; David A Largaespada; Nancy Ratner; Sara Osum; Christopher L Moertel
Journal:  Curr Oncol Rep       Date:  2021-03-15       Impact factor: 5.075

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.